Net costs of breast cancer in Colombia: a cost-of-illness study based on administrative claims databases.

Breast cancer Cost-of-illness study Net costs

Journal

Cost effectiveness and resource allocation : C/E
ISSN: 1478-7547
Titre abrégé: Cost Eff Resour Alloc
Pays: England
ID NLM: 101170476

Informations de publication

Date de publication:
02 Jul 2024
Historique:
received: 06 10 2023
accepted: 24 06 2024
medline: 3 7 2024
pubmed: 3 7 2024
entrez: 3 7 2024
Statut: epublish

Résumé

Breast Cancer (BC) is associated with substantial costs of healthcare; however, real-world data regarding these costs in Colombia is scarce. The contributory regime provides healthcare services to formal workers and their dependents and covers almost half of the population in Colombia. This study aims to describe the net costs of healthcare in women with BC covered by the contributory regime in Colombia in 2019 from the perspective of the Colombian Health System. The main data source was the Capitation Sufficiency Database, an administrative database that contains patient-level data on consumption of services included in the National Formulary (PBS, in Spanish Plan de Beneficios en Salud). Data on consumption of services not included in the PBS (non-PBS) were calculated using aggregated data from MIPRES database. All direct costs incurred by prevalent cases of BC, from January 1 to December 31, 2019, were included in the analysis. The net costs of the disease were estimated by multiplying the marginal cost and the expected number of cases with BC by region and age group. Marginal costs were defined as the costs of services delivered to patients with BC after subtracting the expected costs of health services due to age, comorbidity burden or region of residence. To calculate these costs, we used Propensity Score Matching in the main analysis. All costs were expressed in 2019 international dollars. Productivity losses, transportation expenses, and caregiving costs were not included. A total of 46,148 patients with BC were identified. Total net costs were $387 million (95% CI $377 to $396 million), 60% associated with non-PBS services. Marginal costs were $8,366 (95% Confidence Interval $8,170 to $8,573), with substantial variations between regions age groups (from $3,919 for older patients in the Amazonia region to $10,070 for younger patients in the Pacific region). The costs for PBS services were higher for ambulatory services and for patients who died during 2020. BC imposes a substantial economic burden for the Colombian Health System with important variations in net costs between regions and age groups. Patients near death and ambulatory services were associated with higher costs of healthcare.

Sections du résumé

BACKGROUND BACKGROUND
Breast Cancer (BC) is associated with substantial costs of healthcare; however, real-world data regarding these costs in Colombia is scarce. The contributory regime provides healthcare services to formal workers and their dependents and covers almost half of the population in Colombia. This study aims to describe the net costs of healthcare in women with BC covered by the contributory regime in Colombia in 2019 from the perspective of the Colombian Health System.
METHODS METHODS
The main data source was the Capitation Sufficiency Database, an administrative database that contains patient-level data on consumption of services included in the National Formulary (PBS, in Spanish Plan de Beneficios en Salud). Data on consumption of services not included in the PBS (non-PBS) were calculated using aggregated data from MIPRES database. All direct costs incurred by prevalent cases of BC, from January 1 to December 31, 2019, were included in the analysis. The net costs of the disease were estimated by multiplying the marginal cost and the expected number of cases with BC by region and age group. Marginal costs were defined as the costs of services delivered to patients with BC after subtracting the expected costs of health services due to age, comorbidity burden or region of residence. To calculate these costs, we used Propensity Score Matching in the main analysis. All costs were expressed in 2019 international dollars. Productivity losses, transportation expenses, and caregiving costs were not included.
RESULTS RESULTS
A total of 46,148 patients with BC were identified. Total net costs were $387 million (95% CI $377 to $396 million), 60% associated with non-PBS services. Marginal costs were $8,366 (95% Confidence Interval $8,170 to $8,573), with substantial variations between regions age groups (from $3,919 for older patients in the Amazonia region to $10,070 for younger patients in the Pacific region). The costs for PBS services were higher for ambulatory services and for patients who died during 2020.
CONCLUSIONS CONCLUSIONS
BC imposes a substantial economic burden for the Colombian Health System with important variations in net costs between regions and age groups. Patients near death and ambulatory services were associated with higher costs of healthcare.

Identifiants

pubmed: 38956674
doi: 10.1186/s12962-024-00562-z
pii: 10.1186/s12962-024-00562-z
doi:

Types de publication

Journal Article

Langues

eng

Pagination

54

Subventions

Organisme : Pfizer (Colombia)
ID : 2021-237

Informations de copyright

© 2024. The Author(s).

Références

International Agency for Research on Cancer - World Health Organization. Global Cancer Observatory. 2020 [28/09/2020]; https://gco.iarc.fr/ .
Fondo Colombiano de Enfermedades de Alto Costo - Cuenta de Alto Costo (CAC). Situacion del cancer en la poblacion adulta atendida en el SGSSS de Colombia, 2021. Bogota, D.C.2022. https://cuentadealtocosto.org/site/wp-content/uploads/2022/08/01_agosto_libro_cancer_2021_final.pdf .
Anderson BO, Ilbawi AM, El Saghir NS. Breast Cancer in low and middle income countries (LMICs): a shifting Tide in Global Health. Breast J. 2015;21(1):111–8.
doi: 10.1111/tbj.12357 pubmed: 25444441
Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJL, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84.
doi: 10.1016/S0140-6736(11)61351-2 pubmed: 21924486
Hisham AN, Yip CH. Spectrum of breast cancer in Malaysian women: overview. World J Surg. 2003;27(8):921–3. Epub 2003/06/05.
doi: 10.1007/s00268-003-6976-x pubmed: 12784146
Lao C, Mondal M, Kuper-Hommel M, Campbell I, Cameron MP, Lawrenson R. Breast cancer costs in New Zealand’s public health system. N Z Med J. 2021;134(1545):36–46. Epub 2021/11/18.
pubmed: 34788270
Max W, Sung H-Y, Stark B. The economic burden of breast cancer in California. Breast Cancer Res Treat. 2009;116(1):201–7.
doi: 10.1007/s10549-008-0149-4 pubmed: 18683041
Tarricone R. Cost-of-illness analysis. What room in health economics? Health policy. (Amsterdam Netherlands). 2006;77(1):51–63. Epub 2005/09/06.
doi: 10.1016/j.healthpol.2005.07.016
Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6(3):177–9. Epub 2000/09/26.
doi: 10.1136/ip.6.3.177 pubmed: 11003181 pmcid: 1730654
Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. PharmacoEconomics. 2009;27(3):199–209. Epub 2009/04/10.
doi: 10.2165/00019053-200927030-00003 pubmed: 19354340
Gamboa Ó, Buitrago LA, Lozano T, Dieleman S, Gamboa C, Guzmán ÉL, et al. Costos directos de la atención del cáncer de mama en Colombia. Rev Colomb Cancerol. 2016;20(2):52–60.
doi: 10.1016/j.rccan.2016.02.003
Franco S, Lobaton JF, Aruachan S, Montoya ME, Rojas G, Londoño PA, et al. PCN210 resource utilization and cost for women with Advanced Hr+/Her2- breast Cancer in Colombian Health Care settings. Value Health. 2019;22:S476.
doi: 10.1016/j.jval.2019.09.406
Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013;33(3):411–7. Epub 2014/03/22.
pubmed: 24652177
Chicaíza-Becerra L, García-Molina M, Gamboa O, Castañeda-Orjuela C. ErbB2 + metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country. Rev Salud Publica (Bogota). 2014;16(2):270–80. Epub 2014/11/11.
doi: 10.15446/rsap.v16n2.31690 pubmed: 25383500
Moreno JA, Muñoz-Galindo IM, Guarin NE, Diaz JA, Arevalo HO. Direct costs of Health care for breast Cancer, the case of a Health Manteinance Organization in Colombia. Value Health. 2015;18(3):A254.
doi: 10.1016/j.jval.2015.03.1480
Inotai A, Abonyi-Tóth Z, Rokszin G, Vokó Z. Prognosis, cost, and occurrence of colorectal, lung, breast, and prostate Cancer in Hungary. Value Health Reg Issues. 2015;7:1–8. Epub 2015/09/01.
doi: 10.1016/j.vhri.2015.03.020 pubmed: 29698146
Rosen AB, Aizcorbe A, Highfill T, Chernew ME, Liebman E, Ghosh K, et al. Attribution of Health Care costs to diseases: does the Method Matter? Measuring and modeling Health Care costs. National Bureau of Economic Research, Inc; 2016. pp. 173–210.
Guerrero R, Gallego AI, Becerril-Montekio V, Vásquez J. [The health system of Colombia]. Salud Publica Mex. 2011;53 Suppl 2:s144-55. Epub 2011/09/09. Sistema de salud de Colombia.
Torres GF, Amaya JA, Buitrago G. Attributable costs of Lung Cancer for the Colombian Health System: a cost-of-illness study. Value Health Reg Issues. 2022;30:120–6. Epub 2022/03/29.
doi: 10.1016/j.vhri.2022.02.004 pubmed: 35344754
Rojas A, Fernández C, Beltrán L, Díaz I. Cifras financieras del sector salud: recobros al fosyga por tecnologías en salud no incluidas en El plan de beneficios 2009–2014. Bogotá: Ministerio de Salud y Protección Social; 2015.
Barlow WE. Overview of methods to estimate the medical costs of cancer. Med Care. 2009;47(7 Suppl 1):S33–6. Epub 2009/06/19.
doi: 10.1097/MLR.0b013e3181a2d847 pubmed: 19536013 pmcid: 2719842
The World Bank. PPP conversion factor, GDP (LCU per international $) - Colombia. 2019 [20/06/2022]; https://data.worldbank.org/indicator/PA.NUS.PPP?locations=CO .
Bolívar Varga MC, Caravalli A, Darío A, Hurtado Cárdenas GE, Torres Ovalle G, Linares Cifuentes JC, et al. Estudio De Suficiencia Y De Los Mecanismos De ajuste de riesgo de la unidad de pago por capitación para garantizar El plan obligatorio de salud en El año 2013. Bogotá: Ministerio de Salud y Protección Social; 2014.
Bautista Ico EA. Revisión de la legislación y la afiliación en salud para proponer las características del registro único nacional de afiliados del Sistema General de Seguridad Social en Salud 2006.
Ministerio de Salud y de la Protección Social. SISPRO - Sistema Integrado de Información de la Protección Social. 2021 [30/02/2021]; https://www.sispro.gov.co/Pages/Home.aspx .
Saldaña Espinel LE, Patiño Benavidez AF, Rozo Agudelo N, Gamboa Garay OA, Paneso Echeverry JE, Bernal Gutierrez M, et al. Estimating breast, stomach, and colorectal cancer incidence in Colombia through administrative database algorithms: a systematic review of literature and real-world data study. J Clin Oncol. 2021;39(15suppl):e18810–e.
doi: 10.1200/JCO.2021.39.15_suppl.e18810
Ministerio de Salud y de la Protección Social. Circular 06 de 2018. 2022 [03/07/2022]; https://www.minsalud.gov.co/salud/MT/Paginas/circular-06-de-2018.aspx .
CIRCULAR NÚMERO 04 DE. 2018, (2018).
Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLoS ONE. 2010;5(7):e11501. Epub 2010/07/17.
doi: 10.1371/journal.pone.0011501 pubmed: 20634976 pmcid: 2901386
Palacios A, Rojas-Roque C, González L, Bardach A, Ciapponi A, Peckaitis C, et al. Direct Medical costs, Productivity loss costs and Out-Of-Pocket expenditures in women with breast Cancer in Latin America and the Caribbean: a systematic review. PharmacoEconomics. 2021;39(5):485–502. Epub 2021/03/31.
doi: 10.1007/s40273-021-01014-9 pubmed: 33782865
Perea AH, Rosselli D. Immediate versus delayed breast reconstruction in breast cancer patients in Colombia: a costutility analysis. Biomedica. 2018;38(3):363–78. Epub 2018/10/20.
doi: 10.7705/biomedica.v38i3.3705 pubmed: 30335242
Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Adjusting for comorbidities in cost of illness studies. J Med Econ. 2015;18(1):12–28. Epub 2014/09/26.
doi: 10.3111/13696998.2014.969434 pubmed: 25253504
Mihaylova B, Briggs A, O’Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897–916. Epub 2010/08/28.
doi: 10.1002/hec.1653 pubmed: 20799344
Arrow KJ, Lind RC. Uncertainty and the Evaluation of Public Investment Decisions. Am Econ Rev. 1970;60(3):364–78.
Lao C, Mondal M, Kuper-Hommel M, Campbell I, Lawrenson R. What affects the public healthcare costs of breast cancer in New Zealand? Asia Pac J Clin Oncol. 2022. Epub 2022/09/18.
Mohar A, Bargalló E, Ramírez MT, Lara F, Beltrán-Ortega A. [Available resources for the treatment of breast cancer in Mexico]. Salud Publica Mex. 2009;51 Suppl 2:s263-9. Epub 2010/01/09. Recursos disponibles para el tratamiento del cáncer de mama en México.
OECD. OECD Reviews of Health Systems: Colombia 20162015.
Murcia E, Aguilera J, Wiesner C, Pardo C. Oncology services supply in Colombia. Colombia Médica. 2018;49:89–96.
doi: 10.25100/cm.v49i1.3620 pubmed: 29983468 pmcid: 6018814
Statements of Antitrust Enforcement Policy in Health Care. In: U.S. Department of Justice and the Federal Trade Commission, editor. Washington, D.C. 1996.
Fonseca Salguero MA, Martinez Peñuela DA. Caracterización de peticiones, quejas y reclamos del SGSSS en Colombia en 2014–2019: retos y perspectivas.
Cáncer de Mama. Instituto Nacional de Cancerología - Ministerio de Salud y de Protección Social. 2022 [cited 08/11/2020]; https://www.cancer.gov.co/conozca-sobre-cancer-1/informacion-sobre-cancer-para-pacientes/tipos-cancer/cancer-mama .

Auteurs

Gabriel Fernando Torres (GF)

Instituto de Investigaciones Clínicas, Universidad Nacional de Colombia, Carrera 45 # 26-85, Bogotá, 111321, Colombia. gftorresa@unal.edu.co.

Brigitte Alejandra Alarcón (BA)

Pfizer S.A.S, Av. Suba #95-66, Bogotá, 112111, Colombia.

Juan Manuel Reyes-Sanchez (JM)

Pfizer S.A.S, Av. Suba #95-66, Bogotá, 112111, Colombia.

Natalia Castaño-Gamboa (N)

Pfizer S.A.S, Av. Suba #95-66, Bogotá, 112111, Colombia.

Giancarlo Buitrago (G)

Instituto de Investigaciones Clínicas, Universidad Nacional de Colombia, Carrera 45 # 26-85, Bogotá, 111321, Colombia.
Hospital Universitario Nacional, Calle 44 # 59-75, Bogotá, 111321, Colombia.

Classifications MeSH